Close Menu

NEW YORK (GenomeWeb) – A new study suggests that it may be feasible to use differentially expressed microRNAs as a window for predicting prostate cancer recurrence in individuals treated with radical prostatectomy surgery.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.